Poor response to danazol in hemophilia

In: Blood · 1985 · vol. 65(1) , pp. 211–213 · doi:10.1182/blood.v65.1.211.211 · PMID:3917312 · W15682518
article OA: bronze CC0 ⤵ 7 in-corpus citations
AI-generated summary by claude@2026-06, 2026-06-08

Danazol treatment in hemophilia patients showed minimal and questionable benefits alongside significant side effects including muscle cramps, rash, and hepatic dysfunction.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

We gave danazol (600 mg/day orally for 14 days) to eight adults with mild or moderate hemophilia A, one with severe hemophilia A, and one with moderate hemophilia B. In the patient with severe hemophilia A, the levels of factor VIII two to four days after an infusion of factor VIII concentrate were higher than expected, suggesting a prolonged half-life. In one patient with mild hemophilia A, a questionable slight increase in factor VIII was noted at the end of the study. No change was seen in factor levels of other subjects. Therapy was terminated early, at eight days, in a patient who developed severe muscle cramps, and at ten days in a patient with a severe rash. Another patient developed hepatic dysfunction three days after completing the 14-day trial. In this trial, the side effects of danazol outweighed its meager and questionable benefits.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (2)

Cited by (7)

Source provenance

openalex
last seen: 2026-05-14T05:56:02.807635+00:00
License: CC0 · commercial use OK